You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • AB0188 Combination therapy with adalimumab plus methotrexate reduces circulating levels of pro-matrix matalloproteinases-1 and -3 independently of clinical disease activity in patients with rheumatoid arthritis

Article metrics

Article menu
Download PDFPDF
Abstracts accepted for publication
Rheumatoid arthritis - prognosis, predictors and outcome
AB0188 Combination therapy with adalimumab plus methotrexate reduces circulating levels of pro-matrix matalloproteinases-1 and -3 independently of clinical disease activity in patients with rheumatoid arthritis

 

Online download statistics by month:

Online download statistics by month: February 2014 to February 2024

AbstractFullPdf
Feb 2014503
Mar 2014300
Apr 2014100
May 2014300
Jul 2014100
Oct 2014402
Nov 2014200
Dec 2014400
Mar 20151003
Apr 2015300
Jun 2015500
Jul 2015401
Aug 2015400
Sep 2015401
Nov 2015602
Dec 2015100
Jan 2016100
Feb 2016200
Apr 2016100
May 2016400
Jun 2016200
Jul 2016500
Aug 2016400
Sep 2016500
Oct 2016300
Nov 2016300
Dec 2016700
Jan 2017401
Feb 2017200
Mar 2017600
Apr 2017500
May 2017500
Jun 2017500
Aug 2017400
Sep 2017802
Oct 20171000
Nov 2017200
Dec 20171200
Jan 20181000
Mar 2018600
Apr 2018800
May 2018600
Jun 2018600
Jul 2018200
Aug 20181000
Sep 2018800
Oct 2018200
Nov 2018200
Dec 2018800
Jan 2019601
Feb 2019700
Mar 2019600
Apr 2019200
May 2019402
Jun 2019200
Aug 2019200
Oct 2019600
Jul 2020700
Sep 2020900
Oct 2020400
Nov 2020300
Jan 2021200
Jun 2021400
Aug 2021100
Nov 2021200
Dec 2021400
Jan 2022800
Feb 2022200
Mar 2022400
May 2022400
Jul 20221400
Aug 2022600
Sep 2022600
Oct 2022200
Nov 2022400
Dec 2022600
Jan 2023600
Feb 2023400
Mar 2023200
Apr 2023400
May 2023200
Jul 2023400
Aug 2023400
Sep 2023800
Dec 2023600
Feb 2024100
Total396018